Skip to main content
STLN logo

STLN · Starling Oncology, Inc. · Metrics

Track STLN — free
$3.26 +0.06 (+1.88%) Play latest call Q2 2026 earnings call transcript
Market Cap
$326.37M
Shares
101.99M
Volume · Nov 18 4.68M Avg daily vol (3M) 2.45M

STLN metrics

82 of 125 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$3.20
Market cap
$326.37M

Price action

23 metrics
Price change (1W)
-23.8%
Price change (30D)
-50.5%
Price change (3M)
-52.0%
Price change (6M)
-23.8%
Price change (YTD)
-10.1%
Price change (1Y)
-15.1%
Trailing year
Price change (5Y)
-61.0%
52-week high
$7.05
52-week low
$2.39
Change from 52-week high
-54.6%
Change from 52-week low
+34.2%
Annualized volatility
89.0%
Annualized volatility (3M)
112.6%
Implied volatility (30D)
71.7%
IV rank (1Y)
—
IV percentile (1Y)
—
Beta
1.5
RSI (14D)
27.7
Price vs SMA 50
-47.2%
Price vs SMA 200
-33.2%
Avg volume (3M)
2.45M
Relative volume
1.9
Average dollar volume
$12.16M

Company

3 metrics
Sector
Healthcare
Industry
Medical Care Facilities
Shares outstanding
101.99M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
0.6×
reciprocal yield 171.4%
EV / EBITDA
—
EV / EBIT
—
P / sales
0.5×
reciprocal yield 190.1%
P / book
—
FCF yield
5.8%
TTM · current market cap
Buyback yield
—
P / FCF
17.3
reciprocal yield 5.8%
P / operating cash flow
14.1
reciprocal yield 7.1%
Earnings yield
-10.9%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-11-05

Profitability

9 metrics
Gross margin
—
Operating margin
-3.4%
Trailing 12 months
Net margin
-5.7%
Gross profit (TTM)
—
Operating profit (TTM)
−$21.02M
Net income (TTM)
−$35.54M
Trailing 12 months
Diluted EPS (TTM)
$-0.27
FCF margin
3.0%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$6.03
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
$-0.21
EBITDA per diluted share (TTM)
$-0.14
Net income per diluted share (TTM)
$-0.34
Operating cash flow per diluted share (TTM)
$0.22
Free cash flow per diluted share (TTM)
$0.18
Capital expenditures per diluted share (TTM)
$0.04
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
$0.05
Book value per share
$-0.16

Growth

11 metrics
Revenue growth YoY
+24.3%
Year over year
Net income growth YoY
—
Revenue (TTM)
$620.45M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+7.4%
Year over year · more shares
Revenue CAGR (3Y)
+25.8%
Revenue CAGR (5Y)
+21.8%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
—
Return on assets
-18.9%
Debt / equity
—
Current ratio
1.1
EBITDA (TTM)
−$14.41M
Free cash flow (TTM)
$18.83M
Quick ratio
0.8
Interest coverage
-2.8
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
−$35.62M
Latest balance sheet
Cash & equivalents
$36.90M
Total assets
$187.77M
Total debt
$72.52M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$23.10M
Capital expenditures (TTM)
$4.27M
R&D (TTM)
—
SG&A (TTM)
$118.33M
Stock compensation (TTM)
$5.42M
R&D / revenue
—
Stock compensation / revenue
0.9%

Ownership (13F)

9 metrics
13F filers
130
13F filer change QoQ
+11
Institutional ownership
46.2%
Conviction holders (share of 13F filers)
2.3%
Crowding (high-turnover and private-fund holders)
16.0%
Private-fund adviser ownership
14.9%
Active holders' share change QoQ
+11.6%
Holder tenure
8.6
Price vs estimated holder cost
+43.0%

Ownership (registered funds)

1 metrics
Index-fund ownership
9.1%

Short interest

3 metrics
Short interest
6.7%
Latest settlement · 5.4 days to cover
Days to cover
5.4d
Short-squeeze score
64 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$1.95M
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1799191 CUSIP 68236X100 13F (30d) 140 filings 127 filers Visit website Investor relations